ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIIES (Tables)

12 Months Ended

Dec. 31, 2022

Accounting Policies [Abstract]

Schedule of Revenue from Strategic Partnering Collaboration Agreements and Research Activity Grants as a Percentage of Total Revenues

Revenues from major collaboration agreements and research activity grants as a percentage of total revenues were as follows:

	Year Ended December 31,
	2022		2021		2020
Novartis Institutes for BioMedical Research, Inc.	36	%	34	%	4	%
Kite Pharma, Inc.	35	%	23	%	24	%
Biogen MA, Inc.	26	%	38	%	24	%
Sanofi S.A.	3	%	3	%	5	%
Pfizer Inc.	—	%	—	%	40	%

Schedules of Percentage of Accounts Receivable by Collaboration Partners

As of December 31, 2022 and 2021, the percentage of accounts receivable by collaboration partners who individually accounted for 10% or more of accounts receivable were as follows:

	As of December 31,
	2022		2021
Novartis Institutes for BioMedical Research, Inc.	59	%	32	%
Kite Pharma, Inc.	19	%	2	%
Biogen MA, Inc.	14	%	46	%
Sanofi S.A.	—	%	11	%

Schedule of Cash and Cash Equivalents

A reconciliation of cash, cash equivalents, and restricted cash reported within the accompanying Consolidated Balance Sheets to the amounts reported within the accompanying Consolidated Statements of Cash Flows is as follows (in thousands):

	As of December 31,
	2022		2021		2020
Cash and cash equivalents	$	100,444	$	178,872	$	131,329
Non-current restricted cash	1,500		1,500		1,500
Cash, cash equivalents, and restricted cash as reported within the Consolidated Statements of Cash Flows	$	101,944	$	180,372	$	132,829

Restrictions on Cash and Cash Equivalents

A reconciliation of cash, cash equivalents, and restricted cash reported within the accompanying Consolidated Balance Sheets to the amounts reported within the accompanying Consolidated Statements of Cash Flows is as follows (in thousands):

	As of December 31,
	2022		2021		2020
Cash and cash equivalents	$	100,444	$	178,872	$	131,329
Non-current restricted cash	1,500		1,500		1,500
Cash, cash equivalents, and restricted cash as reported within the Consolidated Statements of Cash Flows	$	101,944	$	180,372	$	132,829